Agios Pharmaceuticals Obtains $78,000,000 Series C Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=f877cbf2-5e0b-42ec-9a73-e2410af734d1&Preview=1 - Date
11/17/2011 - Company Name
Agios Pharmaceuticals - Mailing Address
38 Sidney Street 2nd Floor Cambridge, MA 02139-4169 - Company Description
Agios is a biopharmaceutical company at the forefront of one of the most exciting new areas of cancer research: cancer metabolism. Cancer metabolism represents a breakthrough understanding of how cancer cells become addicted to using more nutrients than normal cells to ensure their survival and growth. - Website
http://www.agios.com - Transaction Type
Venture Equity - Transaction Amount
$78,000,000 - Transaction Round
Series C - Proceeds Purposes
The proceeds of this financing will be used to advance the company’s rapidly emerging portfolio of cancer metabolism therapeutics into the clinic and to expand research and development into inborn errors of metabolism (IEMs), a group of genetic disorders with high unmet medical need. - M&A Terms
- Venture Investor
Celgene Corporation - Venture Investor
Flagship Ventures - Venture Investor
ARCH Venture Partners - Venture Investor
Third Rock Ventures
